Abstract: The present invention relates to a method of producing sesquiterpene lactones of the thapsigargin family, the method comprising the steps of: (a) culturing plant cells of the genus Thapsia in a nutrient medium in a suspension cell culture, wherein the cells produce one or more sesquiterpene lactones of the thapsigargin family; and (b) recovering one or more sesquiterpene lactones of the thapsigargin family produced in (a). The present invention further relates to a suspension cell culture comprising plant cells of the genus Thapsia, wherein the plant cells are capable of producing one or more sesquiterpene lactones of the thapsigargin family and to a plant cell biomass comprising plant cells of the genus Thapsia obtained from said suspension cell culture.

Abstract: The present invention relates to an antibody preparation comprising modified antibodies of an animal or derivatives or fragments thereof, specific for an antigen, characterized in that the antibodies or derivatives or fragments thereof comprise an N-glycan structure free of fucose and xylose, and at least 90%, preferably at least 95%, more preferred at least 99%, most preferred at least 100% of the modified antibodies, derivatives or fragments thereof lack a C-terminal lysine residue.

Abstract: The present invention relates to a method of producing Ingenol, Ingenol esters and/or Tiglian-3-one derivatives, the method comprising the steps of: (a) culturing plant cells obtained from a plant selected from the family Euphorbiaceae in a nutrient medium in a suspension cell culture, wherein the cells produce Ingenol, one or more Ingenol esters and/or one or more Tiglian-3-one derivatives; and (b) recovering the Ingenol, the one or more Ingenol esters and/or the one or more Tiglian-3-one derivatives produced in (a). The present invention further relates to a plant suspension cell culture, wherein the cells are obtained from a plant selected from the family Euphorbiaceae, and wherein the plant cells produce Ingenol and/or one or more Ingenol ester and/or one or more Tiglian-3-one derivatives.

Abstract: The present invention relates to a method of producing Ingenol, Ingenol esters and/or Tiglian-3-one derivatives, the method comprising the steps of: (a) culturing plant cells obtained from a plant selected from the family Euphorbiaceae in a nutrient medium in a suspension cell culture, wherein the cells produce Ingenol, one or more Ingenol esters and/or one or more Tiglian-3-one derivatives; and (b) recovering the Ingenol, the one or more Ingenol esters and/or the one or more Tiglian-3-one derivatives produced in (a). The present invention further relates to a plant suspension cell culture, wherein the cells are obtained from a plant selected from the family Euphorbiaceae, and wherein the plant cells produce Ingenol and/or one or more Ingenol ester and/or one or more Tiglian-3-one derivatives.

Abstract: The present invention relates to a method of producing sesquiterpene lactones of the thapsigargin family, the method comprising the steps of: (a) culturing plant cells of the genus Thapsia in a nutrient medium in a suspension cell culture, wherein the cells produce one or more sesquiterpene lactones of the thapsigargin family; and (b) recovering one or more sesquiterpene lactones of the thapsigargin family produced in (a). The present invention further relates to a suspension cell culture comprising plant cells of the genus Thapsia, wherein the plant cells are capable of producing one or more sesquiterpene lactones of the thapsigargin family and to a plant cell biomass comprising plant cells of the genus Thapsia obtained from said suspension cell culture.

Abstract: The present invention relates to an antibody preparation comprising modified antibodies of an animal or derivatives or fragments thereof, specific for an antigen, characterized in that the antibodies or derivatives or fragments thereof comprise an N-glycan structure free of fucose and xylose, and at least 90%, preferably at least 95%, more preferred at least 99%, most preferred at least 100% of the modified antibodies, derivatives or fragments thereof lack a C-terminal lysine residue.

Abstract: The present invention relates to an antibody preparation comprising modified antibodies of an animal or derivatives or fragments thereof, specific for an antigen, characterized in that • the antibodies or derivatives or fragments thereof comprise an N-glycan structure free of fucose and xylose, and • at least 90%, preferably at least 95%, more preferred at least 99%, most preferred at least 100% of the modified antibodies, derivatives or fragments thereof lack a C-terminal lysine residue.

Abstract: The invention relates to the production of alkaloids from Liliaceae cell culture.

Abstract: The present invention relates to the production of alkaloids from Liliaceae cell culture.

Abstract: A method of amplifying gene expression in a moss plant cell or moss tissue, DNA constructs therefor, moss plant cells and uses thereof for the production of protein.

Abstract: The present invention relates to the production of alkaloids from Liliaceae cell culture.

Abstract: Disclosed are isolated nucleic acid molecules encoding wild type nucleus derived moss expression promoting regions (MEPRs) as well as a method for producing recombinant polypeptides using such MEPRs.

Abstract: Bryophyte plants and bryophyte plant cells comprising dysfunctional fucT and xylT genes and an introduced glycosyltransferase gene, methods for the production of glycosylated proteins therewith, vectors and uses thereof.

Abstract: The present invention relates to a method for producing heterologous glycosylated proteins in non-animal eukaryotic cells such as in transformed bryophyte, yeast, ciliate or algae cells. In particular, the method relates to a method for producing glycosylated proteins comprising animal glycosylation patterns—comprising sialic acid residues—, such as pharmaceutical proteins for use in mammals, e.g. humans, in bryophyte cells such as those of Physcomitrella patens, the genetic material required therefore, such as DNA and RNA, vectors, host cells, methods of introducing genetic material there into, and uses thereof. Furthermore, the present invention relates to novel polypeptides and proteins obtained by the method according to the invention. Moreover, the present invention provides a method of producing sialic acid or CMP-sialic acid in a transformed non-mammalian eukaryotic cell, tissue or organism.

Abstract: The invention discloses DNA molecules encoding galactosyltransferases, recombinant host cells, tissues or organisms comprising dysfunctional galactosyltransferase gene(s), recombinant host cells, tissues or organisms comprising an introduced functional galactosyltransferase gene, methods for the production of proteins therewith, methods for the production of galactosyltransferase and vectors and uses thereof.

Abstract: The present invention relates to an antibody preparation comprising modified antibodies of an animal or derivatives or fragments thereof, specific for an antigen, characterized in that • the antibodies or derivatives or fragments thereof comprise an N-glycan structure free of fucose and xylose, and • at least 90%, preferably at least 95%, more preferred at least 99%, most preferred at least 100% of the modified antibodies, derivatives or fragments thereof lack a C-terminal lysine residue.

Abstract: Disclosed are isolated nucleic acid molecules encoding wild type nucleus derived moss expression promoting regions (MEPRs) as well as a method for producing recombinant polypeptides using such MEPRs.

Abstract: Disclosed are isolated nucleic acid molecules encoding wild type nucleus derived moss expression promoting regions (MEPRs) as well as a method for producing recombinant polypeptides using such MEPRs.

Abstract: A method of amplifying gene expression in a moss plant cell or moss tissue, DNA constructs therefor, moss plant cells and uses thereof for the production of protein.

Abstract: The present invention relates to a method for producing heterologous glycosylated proteins in non-animal eukaryotic cells such as in transformed bryophyte, yeast, ciliate or algae cells. In particular, the method relates to a method for producing glycosylated proteins comprising animal glycosylation patterns—comprising sialic acid residues—, such as pharmaceutical proteins for use in mammals, e.g. humans, in bryophyte cells such as those of Physcomitrella patens, the genetic material required therefore, such as DNA and RNA, vectors, host cells, methods of introducing genetic material there into, and uses thereof. Furthermore, the present invention relates to novel polypeptides and proteins obtained by the method according to the invention. Moreover, the present invention provides a method of producing sialic acid or CMP-sialic acid in a transformed non-mammalian eukaryotic cell, tissue or organism.